Search
Innovative Drug Concept Thrives as BeiGene and Others Surge to Record Levels
2025-04-30 /
Read about 0 minute
Author：小编
During the first quarter of 2025, Chinese pharmaceutical companies sealed over 20 global licensing agreements, signaling a robust market with BD transactions anticipated to soar to unprecedented heights. The innovative drug sector continues to buzz with activity, exemplified by stocks like BeiGene and InnoCare scaling new peaks, while Kelun Pharmaceutical and Yifang Biopharmaceuticals also registered significant gains. This momentum underscores China's ascending position in the global pharmaceutical R&D landscape and the burgeoning innovation prowess of domestic enterprises.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
